Correction to: Effectiveness of Switching from Reference Product Infiximab to Infiximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study

Stephanie L. Ho¹ · Fang Niu² · Suresh Pola³ · Fernando S. Velayos⁴ · Xian Ning¹ · Rita L. Hui⁵

Published online: 6 April 2020
© The Author(s) 2020

Correction to: BioDrugs

<https://doi.org/10.1007/s40259-020-00409-y>

The article Effectiveness of Switching from Reference Product Infiximab to Infiximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study, written by Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning and Rita L. Hui, was originally published electronically on 26 February 2020 without open access. With the author(s)' decision to opt for Open Choice the copyright of the article changed on 30 March 2020 to © The Author(s) 2020 and the article is forthwith distributed under the terms of a Creative Commons Attribution-NonCommercial 4.0 International License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original

author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40259-020-00409-y>.

✉ Rita L. Hui
Rita.L.Hui@kp.org

Stephanie L. Ho
Stephanie.L.Ho@kp.org

Fang Niu
Fang.Niu@kp.org

Suresh Pola
Suresh.Pola@kp.org

Fernando S. Velayos
Fernando.Velayos@kp.org

Xian Ning
Jennie.X.Ning@kp.org

¹ Drug Use Management, Kaiser Permanente, Oakland, CA, USA

² Pharmacy Outcomes Research Group, Kaiser Permanente, Downey, CA, USA

³ Department of Gastroenterology, Southern California Permanente Medical Group, San Diego, CA, USA

⁴ Division of Gastroenterology and Hepatology, The Permanente Medical Group, San Francisco, CA, USA

⁵ Pharmacy Outcomes Research Group, Kaiser Permanente, 1800 Harrison St #1301, Oakland, CA 94612, USA